- Home
- JPC vs CRNX Comparison
JPC vs CRNX Comparison
Compare JPC & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- CRNX
- Stock Information
- Founded
- JPC 2003
- CRNX 2008
- Country
- JPC United States
- CRNX United States
- Employees
- JPC N/A
- CRNX N/A
- Industry
- JPC Investment Managers
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- CRNX Health Care
- Exchange
- JPC Nasdaq
- CRNX Nasdaq
- Market Cap
- JPC 2.5B
- CRNX 2.8B
- IPO Year
- JPC N/A
- CRNX 2018
- Fundamental
- Price
- JPC $8.01
- CRNX $30.48
- Analyst Decision
- JPC
- CRNX Strong Buy
- Analyst Count
- JPC 0
- CRNX 10
- Target Price
- JPC N/A
- CRNX $75.00
- AVG Volume (30 Days)
- JPC 998.5K
- CRNX 613.8K
- Earning Date
- JPC 01-01-0001
- CRNX 08-07-2025
- Dividend Yield
- JPC 7.57%
- CRNX N/A
- EPS Growth
- JPC N/A
- CRNX N/A
- EPS
- JPC N/A
- CRNX N/A
- Revenue
- JPC N/A
- CRNX $760,000.00
- Revenue This Year
- JPC N/A
- CRNX $402.12
- Revenue Next Year
- JPC N/A
- CRNX $770.88
- P/E Ratio
- JPC N/A
- CRNX N/A
- Revenue Growth
- JPC N/A
- CRNX N/A
- 52 Week Low
- JPC $5.94
- CRNX $24.10
- 52 Week High
- JPC $7.36
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- JPC 63.85
- CRNX 42.06
- Support Level
- JPC $7.88
- CRNX $29.73
- Resistance Level
- JPC $8.00
- CRNX $31.44
- Average True Range (ATR)
- JPC 0.04
- CRNX 1.04
- MACD
- JPC -0.00
- CRNX -0.18
- Stochastic Oscillator
- JPC 87.50
- CRNX 6.93
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.